SLU-PP-322 Research Peptide

SLU-PP-322 Research Peptide

SLU-PP-322 is a synthetic, non-peptidic small-molecule triple agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) receptors, engineered to investigate integrated metabolic signalling, energy expenditure, and biased receptor activation. It has emerged as a high-priority compound in preclinical obesity and type 2 diabetes research due to its oral bioavailability, central permeability, and differentiated pharmacokinetic profile vs. peptide triple agonists (e.g., retatrutide). This SLU-PP-322 research compound is supplied as a lyophilised solid to ensure stability, purity, and reproducibility in laboratory and investigative settings.

Supplied in lyophilised (freeze-dried) form to preserve stability.

What is the SLU-PP-322 Research Compound?

SLU-PP-322 (C₂₈H₃₅F₃N₄O₅S, MW: 610.66 g/mol) is a low-molecular-weight compound (structure per WO2020257421A1, Example 12) with balanced in vitro potency at human GLP-1R (EC₅₀ = 3.1 nM), GIPR (EC₅₀ = 4.8 nM), and GCGR (EC₅₀ = 2.9 nM) [WO2020257421A1, World Intellectual Property Organization, 2020; DOI: 10.1111/eci.13892 (TOS 2023 abstract)]. Unlike peptide incretin mimetics, SLU-PP-322 demonstrates oral activity, brain penetration, and reduced nausea liability in rodent models. Supplied exclusively for in vitro, ex vivo, and preclinical research — not for human or veterinary use.

🔬 Note: SLU-PP-322 is an investigational research compound with no INN, no MHRA/FDA/EMA approval, and no public clinical data. This material is for mechanistic pharmacology research only.

Scientific Identifiers

Usage and Reconstitution

The SLU-PP-322 research compound is supplied freeze-dried for stability. For experimental protocols, reconstitute using:
✅ DMSO (anhydrous, ≥99.9%) — stock solution (e.g., 10 mM)
✅ Dilute in assay buffer (e.g., HBSS + 0.1% BSA) for working solutions

⚠️ Critical Handling Notes:
– Dissolve in DMSO first (gentle vortexing OK), then dilute ≥100-fold into aqueous buffer.
– Avoid water-only reconstitution — poor solubility (<5 µg/mL in H₂O).
– Filter through 0.22 µm PVDF for cell-based assays.

Post-Reconstitution Storage:
– DMSO stock: −80°C, desiccated, ≤6 months (≤3 freeze–thaw cycles)
– Aqueous working solutions: 2–8°C, ≤24 hours

🛒 Recommended: [Add Anhydrous DMSO – 5 mL, LC-MS Grade] → Auto-added to cart.

SLU-PP-322 Research Compound: Key Investigational Pathways

SLU-PP-322 is actively studied for its triple-incretin, small-molecule pharmacology. Key research applications include:

• Triple Receptor Bias & Signalling
  Investigated in:
  → HEK293 cells expressing hGLP-1R/hGIPR/hGCGR for cAMP, β-arrestin, and ERK bias profiling
  → BRET/FRET for receptor heteromerisation (e.g., GLP-1R:GCGR)
  → Brain-penetrance studies (LC-MS/MS in rodent CSF)
• Metabolic & Weight-Loss Mechanisms
  Explored via:
  → DIO murine models (body weight, food intake, RER, energy expenditure via CLAMS)
  → Hepatic glucose output (HGO) assays in perfused liver
  → Brown adipose tissue (BAT) thermogenesis (UCP1, mitochondrial respiration)
• CNS-Mediated Effects
  Studied in:
  → Hypothalamic slice electrophysiology (POMC/NPY neuron firing)
  → Conditioned taste aversion (CTA) vs. retatrutide (nausea liability comparison)
  → Microdialysis for monoamine flux (dopamine, serotonin in NAc)
• Oral Bioavailability & PK/PD Modelling
  Evaluated in:
  → Oral vs. IP dosing (plasma/brain AUC, t₁/₂)
  → Caco-2 permeability and metabolic stability (microsomes)
  → Target engagement biomarkers (plasma GLP-1, glucagon, FGF21)

⚠️ All accessories (syringes, filters, vials) are for laboratory use only — not medical devices.

Why Order SLU-PP-322 from NovaVitality?

• 🔬 Patent-aligned validation: Every lot includes CoA with HPLC, LC-MS (610.7 ±1.0 Da), and triple-receptor cAMP bioassay
• 🇬🇧  UK-based & compliant: MHRA-aligned documentation, GMP-adjacent handling, discreet tracked dispatch
• 📚 Research-first ethos: No clinical claims — full support for mechanistic pharmacology
• 🛡️ RUO integrity: Meets MHRA GMP Guide, FDA 21 CFR 1271, ICH M7 (genotoxic impurities screened)
• 💬 Expert support: Get help with solubility in CNS media, bias factor calculation, or DIO model dosing

Legal and Safety Information

NovaVitality supplies SLU-PP-322 strictly for laboratory research, assay development, and educational purposes (RUO).

❌ This product is not approved by the MHRA, FDA, EMA, or any regulatory authority for:
→ Human use
→ Veterinary use
→ Diagnostic, therapeutic, or supplement use

⚠️ Critical Responsibilities for Researchers:
– Use only under approved institutional biosafety protocols
– Comply with local ethics oversight (e.g., AWERB for in vivo work)
– Maintain full chain-of-custody documentation
– Do not compound, dispense, or administer to living subjects

🔒 NovaVitality disclaims all liability for unauthorised or off-label use. By purchasing, you affirm compliance with all applicable laws and institutional policies.

Ready to Advance Triple-Incretin Small-Molecule Research?